LGT Fund Management Co Ltd. raised its position in shares of Eli Lilly and Company (NYSE:LLY – Get Rating) by 205.1% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 61,019 shares of the company’s stock after purchasing an additional 41,019 shares during the quarter. Eli Lilly and comprises 2.4% of LGT Fund Management Co Ltd.’s portfolio, making the stock its 8th largest holding. LGT Fund Management Co Ltd.’s holdings in Eli Lilly and were worth $17,858,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of LLY. Marietta Wealth Management LLC increased its holdings in shares of Eli Lilly and by 30.3% in the first quarter. Marietta Wealth Management LLC now owns 16,278 shares of the company’s stock valued at $4,662,000 after buying an additional 3,787 shares in the last quarter. Integrated Wealth Concepts LLC increased its stake in Eli Lilly and by 10.3% in the 4th quarter. Integrated Wealth Concepts LLC now owns 17,255 shares of the company’s stock worth $4,766,000 after purchasing an additional 1,613 shares in the last quarter. Central Bank & Trust Co. raised its holdings in Eli Lilly and by 7.4% during the 1st quarter. Central Bank & Trust Co. now owns 2,705 shares of the company’s stock worth $775,000 after buying an additional 186 shares during the period. MBL Wealth LLC purchased a new stake in Eli Lilly and during the first quarter valued at about $212,000. Finally, Massmutual Trust Co. FSB ADV boosted its holdings in shares of Eli Lilly and by 1.9% in the first quarter. Massmutual Trust Co. FSB ADV now owns 5,597 shares of the company’s stock worth $1,603,000 after buying an additional 105 shares during the period. 82.75% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the stock. StockNews.com downgraded shares of Eli Lilly and from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 5th. JPMorgan Chase & Co. lifted their price target on Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. Wells Fargo & Company lifted their target price on Eli Lilly and from $280.00 to $305.00 in a research note on Friday, April 29th. Barclays increased their price target on shares of Eli Lilly and from $333.00 to $355.00 and gave the stock an “overweight” rating in a research report on Thursday, July 7th. Finally, Mizuho boosted their price objective on shares of Eli Lilly and from $315.00 to $356.00 in a research report on Monday, May 2nd. Three analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and has an average rating of “Moderate Buy” and an average price target of $317.00.
Insider Buying and Selling
Eli Lilly and Stock Performance
NYSE:LLY traded up $7.43 during mid-day trading on Friday, hitting $324.15. 71,176 shares of the company’s stock traded hands, compared to its average volume of 2,650,623. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 1.70. The firm has a 50 day moving average of $315.96 and a two-hundred day moving average of $293.19. The firm has a market capitalization of $308.00 billion, a price-to-earnings ratio of 50.51, a price-to-earnings-growth ratio of 2.16 and a beta of 0.35. Eli Lilly and Company has a 12 month low of $220.20 and a 12 month high of $335.33.
Eli Lilly and (NYSE:LLY – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The business had revenue of $6.49 billion during the quarter, compared to the consensus estimate of $6.85 billion. During the same period in the prior year, the company posted $1.87 earnings per share. The firm’s revenue was down 3.7% compared to the same quarter last year. On average, equities analysts forecast that Eli Lilly and Company will post 7.96 earnings per share for the current fiscal year.
Eli Lilly and Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 9th. Shareholders of record on Monday, August 15th will be paid a dividend of $0.98 per share. The ex-dividend date is Friday, August 12th. This represents a $3.92 annualized dividend and a yield of 1.21%. Eli Lilly and’s dividend payout ratio is 62.52%.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- Apple’s Stock Could Be On The Verge Of Another 30% Rally
- Near-Term Headwinds Present An Opportunity In Ross Stores
- If You Hate Speed Cameras, Then You’ll Like Verra Mobility Stock
- Is Sanofi A Buy, Despite Recent Stumbles?
- Institutional Support For TJX Companies May Cap Gains
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.